Results 151 to 160 of about 118,336 (247)

Pharmacists expand access to contingency management in patients with substance use disorders. [PDF]

Ment Health Clin
Salsman M, Colvard M, Beam C, Frey T, Rothbauer K, Eatmon C.   +5 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Paying Community Preceptors in the Family Medicine Clerkship: Trends From a CERA Secondary Analysis. [PDF]

Fam Med
Ringwald BA, Banas D, Farrell M, Macerollo A, Bruce E.   +4 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

A cautionary tale about urban trees: could ecoservice monetary estimates become economic sleights of hand? [PDF]

Bioscience
Van Stan JT, Mueller KE, Wiitala MO, Simmons J, Noren BJ, Lin M, Huang Q, Porada P, Endreny TA.   +8 more
europepmc   +1 more source

Vaccine Incentives Harm Intrinsic Motivation: Evidence From a Priming Experiment. [PDF]

Health Econ
Huynh J, Jacinto C, Huynh J.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Cost-utility analysis of the Circle of Security-Parenting programme to reduce perinatal psychopathology in birthing parents in England. [PDF]

BMJ Open
Wang J, Rosan C, Alyousefi-van Dijk K, Darwin Z, Babalis D, Cornelius V, Waddingham E, Richards L, Pilling S, Fearon P, Fonagy P, Pizzo E.   +11 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis. [PDF]

Front Public Health
Jin S, Hu Z, Jin Y, Lv W, Song Z, Zeng S, Wu M.   +6 more
europepmc   +1 more source